| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | bugallo, ana |
| dc.contributor.author | Muiño, Elena |
| dc.contributor.author | Hervella, Pablo |
| dc.contributor.author | Arias-Rivas, Susana |
| dc.contributor.author | Rodríguez-Yáñez, Manuel |
| dc.contributor.author | Maisterra Santos, Olga |
| dc.contributor.author | Pizarro Gonzálvez, Jesús |
| dc.contributor.author | Bravo Lopez, Susana Belén |
| dc.date.accessioned | 2025-04-04T06:26:04Z |
| dc.date.available | 2025-04-04T06:26:04Z |
| dc.date.issued | 2025-02-27 |
| dc.identifier.citation | Bugallo-Casal A, Muiño E, Bravo SB, Hervella P, Arias-Rivas S, Rodríguez-Yáñez M, et al. NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL. NeuroMolecular Med. 2025 Feb 27;27:18. |
| dc.identifier.issn | 1559-1174 |
| dc.identifier.uri | http://hdl.handle.net/11351/12894 |
| dc.description | Disease modeling; Proteomic analysis; Stem cells |
| dc.description.abstract | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common genetic form of stroke. It is caused by a cysteine-altering variant in one of the 34 epidermal growth factor-like repeat (EGFr) domains of Notch3. NOTCH3 pathogenic variants in EGFr 1–6 are associated with high disease severity, whereas those in EGFr 7–34 are associated with late stroke onset and increased survival. However, whether and how the position of the NOTCH3 variant directly affects the disease severity remains unclear. In this study, we aimed to generate human-induced pluripotent stem cells (hiPSCs) from patients with CADASIL with EGFr 1–6 and 7–34 pathogenic variants to evaluate whether the NOTCH3 position affects the cell phenotype and protein profile of the generated hiPSCs lines. Six hiPSCs lines were generated: two from patients with CADASIL with EGFr 1–6 pathogenic variants, two from patients with EGFr 7–34 variants, and two from controls. Notch3 aggregation and protein profiles were tested in the established six hiPSCs lines. Cell analysis revealed that the NOTCH3 variants did not limit the cell reprogramming efficiency. However, EGFr 1–6 variant position was associated with increased accumulation of Notch3 protein in pluripotent stem cells and proteomic changes related with cytoplasmic reorganization mechanisms. In conclusion, our analysis of hiPSCs derived from patients with CADASIL support the clinical association between the NOTCH3 variant position and severity of CADASIL. |
| dc.language.iso | eng |
| dc.publisher | Springer |
| dc.relation.ispartofseries | NeuroMolecular Medicine;27 |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Malalties cerebrovasculars - Aspectes genètics |
| dc.subject | Cèl·lules mare adultes |
| dc.subject | Anomalies cromosòmiques |
| dc.subject.mesh | CADASIL |
| dc.subject.mesh | /genetics |
| dc.subject.mesh | Induced Pluripotent Stem Cells |
| dc.subject.mesh | Genetic Variation |
| dc.subject.mesh | Stroke |
| dc.title | NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1007/s12017-025-08840-6 |
| dc.subject.decs | cadasil |
| dc.subject.decs | /genética |
| dc.subject.decs | células madre pluripotentes inducidas |
| dc.subject.decs | variación genética |
| dc.subject.decs | accidente cerebrovascular |
| dc.relation.publishversion | https://doi.org/10.1007/s12017-025-08840-6 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Bugallo Casal A] Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. University of Santiago de Compostela (USC), Santiago de Compostela, Spain. [Muiño E] Stroke Pharmacogenomics and Genetics, Sant Pau Institute of Research (IR Sant Pau), Barcelona, Spain. Epilepsy Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Bravo SB] Proteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. [Hervella P] Neuroimaging and Biotechnology Laboratory Group (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. [Arias Rivas S, Rodríguez Yáñez M] Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain. [Maisterra Santos O, Pizarro Gonzálvez J] Unitat de Trastorns de Memòria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Demències, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain |
| dc.identifier.pmid | 40016442 |
| dc.identifier.wos | 001435375600001 |
| dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/825575 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |